Ergothioneine vs Glutathione
Two antioxidants with a 'declines with age, so restore it' pitch — one a diet-derived amino acid with strong observational data and zero outcome trials, the other with a real trial showing supplementation raises the body's own stores.
Ergothioneine
ERGO, the 'longevity vitamin'
A diet-derived amino acid with a dedicated transporter that concentrates it in mitochondria-rich tissue, and strong observational associations between blood levels and healthy aging — but no completed outcome RCT tests supplementation itself.
Full Ergothioneine evidence reviewGlutathione
GSH
Oral glutathione raises body stores in a 6-month RCT (reverses on stopping); but longevity/detox claims are unproven, skin-lightening is modest, and IV is the least-evidenced route.
Full Glutathione evidence reviewSide by side
| Ergothioneine | Glutathione | |
|---|---|---|
| Marketed for | General antioxidant support, healthy aging | Antioxidant, detox, anti-aging, skin |
| Evidence grade | Preclinical / minimal | Clinical data |
| Family | NAD⁺ & mitochondrial | NAD⁺ & mitochondrial |
| Key human source | Cheah & Halliwell 2018 review, IUBMB Life | Oral RCT, Eur J Nutr 2015 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Glutathione has the more direct human evidence: a six-month RCT shows oral supplementation genuinely raises the body's own glutathione stores, though levels drift back after stopping and no trial shows a disease or aging outcome. Ergothioneine's case is entirely observational — blood levels track with healthier aging in cohort studies — but no completed trial has tested whether supplementing it changes anything. Neither has been compared directly.
Ergothioneine fits if
You're drawn to the epidemiological signal and want the compound with a dedicated cellular transporter concentrating it in mitochondria-rich tissue.
Glutathione fits if
You want the compound with actual interventional human data, even though it only measures a biomarker — and consider the cheaper glycine+NAC precursor route first.